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a larger sample size and severity sub-group comparisons is
ongoing.
PST7
DOES ADMINISTRATION MODE AFFECT ITEM HIERARCHY 
IN STROKE SPECIFIC QUALITY OF LIFE MEASURE,
STROKE IMPACT SCALE?—TELEPHONE AND MAIL
ADMINISTRATION METHODS
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OBJECTIVES: The purpose of this study is to further examine
potential mode effect on item difﬁculty hierarchy by taking item
response theory (IRT) approach. Speciﬁc objective is to examine
if the Stroke Impact Scale-16 (SIS-16) items function in the same
way between the two administration modes in item difﬁculty
hierarchy. METHODS: Patients with stroke were identiﬁed using
ICD-9CM in 13 participating Veterans Affairs (VA) hospitals in
administrative database and conﬁrmed by reviewing electronic
medical records. Patients were randomized to mail or telephone
groups to administer SIS-16 at 12-weeks after stroke. Baseline
demographics and severity of stroke were compared. Item difﬁ-
culties and errors associated with the difﬁculties were estimated
with the Rasch model using Winsteps. RESULTS: Telephone and
mail group are composed of 96 and 92 patients, who were com-
parable in terms of demographics and stroke severity. SIS-16
scores distributed without severe ceiling or ﬂoor effects. The
‘walk fast’ was the most difﬁcult and ‘stay sitting without losing
balance’ was the easiest item. The item difﬁculty hierarchy was
maintained in 10 items, but three items, carry heavy object with
affected hand, dress the top part, move from bed to chair, were
as more difﬁcult in telephone survey while reported walk one
block, control bladder, get to the toilet were more difﬁcult in the
mail administration group. However, considering the error asso-
ciated with the difﬁculty showed that all 16 items were within
95% conﬁdence intervals, thereby failing to show signiﬁcant 
Differential Item Functioning (DIF). CONCLUSION: While the
items of the SIS-16 showed some discordance in item hierarchy
across mail and telephone administrations, none of the items
showed signiﬁcant DIF. These ﬁndings suggest that the mode of
administration does not inﬂuence item difﬁculty hierarchies. As
technologies such as internet and emails are more accessible, a
research agenda needs to be developed to facilitate efﬁcient
follow-up.
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OBJECTIVES: Literature incorporating costs of total knee
replacement (TKR) and total hip replacement (THR) other than
inpatient care, follow-up after 90 days, or complications besides
deep vein thrombosis (DVT) and pulmonary embolism (PE) is
lacking. Our objective was to determine the impact of TKR and
THR complications on inpatient and outpatient direct medical
costs over 1 year in the Department of Veterans Affairs (VA).
METHODS: Nationwide VA data were utilized. Direct medical
costs were determined from VA costing methodologies. Utiliza-
tion included labs, x-rays, medications, and inpatient, outpa-
tient, and emergency department visits associated with surgery
or its complications. Complications included DVT, PE, major
hemorrhage (MH), and thrombocytopenia. Mann-Whitney U
tests of median costs were performed by complication within
TKR and THR. RESULTS: The VA spent $121,305,992 caring
for 5309 patients (3424 TKR and 1885 THR). TKR patients
who developed DVT (n = 116) or PE (n = 21) had higher median
(mean ± standard deviation) costs: $17,572 ($21,638 ± $26,942)
versus $14,850 ($17,889 ± $7944, n = 3308, p = 0.001) and
$17,912 ($22,920 ± $17,282) versus $14,882 ($17,985 ± $9189,
n = 3403, p = 0.041), respectively. No differences were found
between TKR patients with MH or thrombocytopenia or
between THR patients with DVT or MH compared to those
without these complications. THR patients who had PE (n = 22)
or thrombocytopenia (n = 19) incurred higher costs: $18,719
($22,833 ± $12,753) versus $16,277 ($18,854 ± $8894, n =
1863, p = 0.046) and $19,831 ($22,740 ± $11,930) versus
$16,277 ($18,861 ± $8914, n = 1866, p = 0.046), respectively.
CONCLUSION: Complications resulted in signiﬁcantly higher
costs, which may reﬂect earlier mortality due to complications.
Lack of health care information from non-VA organizations is a
potential limitation.
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OBJECTIVES: Recombinant human bone morphogenetic
protein (rhBMP2) is a novel biologic therapy that promotes bone
growth at the fracture site. We analyzed the cost-effectiveness of
rhBMP-2 in open tibia fractures in Sweden and Denmark.
METHODS: We developed an economic model to compare
rhBMP-2 + standard of care (soft tissue management and
intramedullary nailing) with standard of care alone. We obtained
clinical data from the BMP-2 Evaluation for Surgery in Tibial
Trauma (BESTT) trial and estimated treatment costs from
national sources such as NORD-DRG for Sweden and DkDRG
for Denmark. Total cost were measured as direct cost plus indi-
rect costs and reported separately. Direct costs were measured as
drug costs plus cost for complications and indirect costs were
valued as lost productivity using average annual salaries. We
assigned utility weights to different grades (Gustillo I–IIIB) of
open tibia fractures to estimate the difference in quality-adjusted-
life-expectancy. We performed the analysis from the health care
payer’s and societal perspectives for a one-year time-horizon. We
focus our analysis on Gustillo grade III (A and B) fractures where
rhBMP-2 is most commonly used. RESULTS: In Sweden, use of
rhBMP-2 (€2800) for grade III open tibia fractures resulted in
an incremental cost of €1684 per patient and in incremental cost-
effectiveness ratio (ICER) of €22,811/QALY. When indirect costs
were included, rhBMP-2 was cost-saving. In Denmark, rhBMP-
2 (€3100) treatment for grade III open tibia fractures resulted in
an incremental cost of €1635 per patient and an ICER of
€17,964/QALY and was cost-saving when productivity loss was
also included. CONCLUSION: From a payer’s perspective,
rhBMP-2 is a cost-effective treatment option in grade III open
tibia fractures for both the Swedish and Danish health care
systems. rhBMP-2 was a cost-saving option from the societal per-
spective, and therefore, a good value for money.
